Regions

Germany
CCDRD AG Headquarter Hoppegarten, near Berlin

  • General Management
  • Business Development
  • Regulatory and Strategic Advice
  • Clinical Operations
  • Project Management of phase I-IV trials
  • Submission services
  • Monitoring of phase II-IV trials in Germany
  • Statistics and Data Management
  • Quality Managment
  • Information Technology
  • General Services / Administration

60-90 days for Clinical Trial Approval

Bulgaria
Sofia

  • Management of three local Phase I units
  • Site identification and management for phase I-IV trials
  • Feasibility evaluation
  • Strong clinical networks and access to qualified sites in oncology, CNS, renal disease, diabetes, dermatology, diabetes, cardiology
  • Regulatory submissions
  • Specialized monitoring of pharmacokinetic studies
  • Monitoring of phase I-IV studies

60-90 days for Clinical Trial Approval

Poland
Poznan

  • Feasibility evaluation of clinical sites
  • Site identification and contracting
  • Strong clinical networks and access to sites in oncology, renal disease, metabolic disease, diabetes, dermatology, ophthalmology
  • Regulatory submissions
  • Monitoring of phase II/III studies

14–60 days for Clinical Trial Approval

Romania
Timisoara

  • Feasibility evaluation of clinical sites
  • Site identification and contracting
  • Strong clinical networks and access to sites in oncology, renal disease, CNS, diabetes, dermatology
  • Regulatory submissions
  • Monitoring of phase II/III studies

60-90 days for Clinical Trial Approval

Turkey
Kayseri, Istanbul, Ankara

  • Management of local Phase I units
  • Site identification and management for phase I-III trials
  • Regulatory submissions for phase I-III trials
  • Monitoring of phase I-III studies

30–60 days for Clinical Trial Approval

Jordan
Amman

  • Management of local Phase I unit
  • Regulatory submissions for phase I trials
  • Monitoring of phase I studies

14-21 days for Clinical Trial Approval

Serbia
Kragujevac

  • Feasibility evaluation of clinical sites
  • Site identification and contracting
  • Regulatory submissions
  • Monitoring of phase II-III studies

60-90 days for Clinical Trial Approval